Compounds > lu 135252
Page last updated: 2024-09-05

lu 135252 and Acute Disease

lu 135252 has been researched along with Acute Disease in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's5 (83.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Buhr, HJ; Eibl, G; Foitzik, T; Forgacs, B; Hotz, HG1
Almeida, AP; Barton, M; Camargos, ER; Chiari, E; Ferreira, AJ; Machado, CR; Rachid, MA; Rocha, LL; Teixeira, AL; Teixeira, MM1
Boemke, W; Busch, T; Deja, M; Donaubauer, B; Ebsen, M; Francis, R; Kaisers, U; Lachmann, R; Petersen, B; Träger, A1
Buhr, HJ; Faulhaber, J; Foitzik, T; Hotz, HG; Kirchengast, M1
Buhr, HJ; Eibl, G; Faulhaber, J; Foitzik, T; Hotz, HG; Kirchengast, M1
Cheng, TO1

Other Studies

6 other study(ies) available for lu 135252 and Acute Disease

ArticleYear
Endothelin A but not endothelin B receptor blockade reduces capillary permeability in severe experimental pancreatitis.
    Pancreas, 2002, Volume: 25, Issue:2

    Topics: Acute Disease; Animals; Blood Flow Velocity; Capillary Permeability; Colon; Endothelin Receptor Antagonists; Male; Pancreas; Pancreatitis; Phenylpropionates; Pyrimidines; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B

2002
Protective role of ETA endothelin receptors during the acute phase of Trypanosoma cruzi infection in rats.
    Microbes and infection, 2004, Volume: 6, Issue:7

    Topics: Acute Disease; Animals; Blood Flow Velocity; Chagas Disease; Disease Models, Animal; Endothelin A Receptor Antagonists; Heart; Humans; Inflammation; Male; Parasitemia; Phenylpropionates; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Trypanosoma cruzi

2004
Low-dose inhalation of an endothelin-A receptor antagonist in experimental acute lung injury: ET-1 plasma concentration and pulmonary inflammation.
    Experimental biology and medicine (Maywood, N.J.), 2006, Volume: 231, Issue:6

    Topics: Acute Disease; Administration, Inhalation; Animals; Blood Pressure; Cardiac Output; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin-1; Inflammation; Lung Diseases; Phenylpropionates; Prospective Studies; Pulmonary Gas Exchange; Pyrimidines; Random Allocation; Swine

2006
Endothelin receptor blockade improves fluid sequestration, pancreatic capillary blood flow, and survival in severe experimental pancreatitis.
    Annals of surgery, 1998, Volume: 228, Issue:5

    Topics: Acute Disease; Animals; Body Fluids; Capillaries; Endothelin Receptor Antagonists; Male; Pancreas; Pancreatitis, Acute Necrotizing; Phenylpropionates; Pyrimidines; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Severity of Illness Index; Survival Rate

1998
Endothelin receptor blockade in severe acute pancreatitis leads to systemic enhancement of microcirculation, stabilization of capillary permeability, and improved survival rates.
    Surgery, 2000, Volume: 128, Issue:3

    Topics: Acute Disease; Animals; Blood Pressure; Capillary Permeability; Endothelin Receptor Antagonists; Hematocrit; Leukocytes; Male; Microcirculation; Oxygen; Pancreas; Pancreatitis; Phenylpropionates; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Survival Rate

2000
Endothelin receptor blockade in congestive heart failure.
    Circulation, 2001, Oct-30, Volume: 104, Issue:18

    Topics: Acute Disease; Antihypertensive Agents; Bosentan; Chronic Disease; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelin-1; Exercise Tolerance; Heart Failure; Hemodynamics; Humans; Phenylpropionates; Pyridines; Pyrimidines; Sulfonamides; Tetrazoles; Treatment Outcome; Vasodilator Agents

2001